办公室实验室环境下髂静脉支架置入术的安全性:4312例非血栓性髂静脉病变的经验
该回顾性研究分析了2012至2024年间在办公室实验室对2642例有症状慢性静脉功能不全(CEAP C3-C6)患者实施的4312例髂静脉支架置入术,术后30天血栓发生率低,且年龄、CEAP临床分级和侧别与30天血栓无显著关联,支持该术式在广泛严重程度的慢性静脉功能不全患者中安全有效。
要点
- 髂静脉支架置入术后30天血栓发生率低,各年龄组和CEAP分级组均较低。
- 在办公室实验室环境下,对非血栓性髂静脉病变行支架置入是安全有效的。
核心结论
- 对有症状的非血栓性髂静脉病变行髂静脉支架置入是安全有效的手术,早期血栓发生率低。
- 年龄、侧别和CEAP临床分级与30天血栓结局无显著关联。
- 研究支持在办公室实验室环境下对广泛严重程度的慢性静脉功能不全患者使用髂静脉支架置入。
研究设计与样本
- 回顾性分析2012至2024年间在办公室实验室实施的4312例髂静脉支架置入术,共2642例有症状慢性静脉功能不全(CEAP C3-C6)患者。
- 患者接受血管内超声(IVUS)评估并置入支架,术后3-7天行髂静脉双功超声随访,第一年3-6个月额外评估,后续每6-12个月随访。
- 术中未使用肝素,术后每日服用氯吡格雷。
主要发现
- 研究人群平均年龄73岁(范围30-108岁),男性39.30%,女性60.70%。
- 按治疗的非血栓性髂静脉病变数量统计的年龄分布:30多岁43例,40多岁151例,50多岁498例,60多岁926例,70多岁1116例,80多岁1035例,90岁以上543例。
- 30天血栓率按年龄组:30多岁0%,40多岁0.01324%,50多岁0.0200%,60多岁0.0118%,70多岁0.0179%,80多岁0.0116%,90岁以上0.0074%。
- 30天血栓率按CEAP临床分级:C3 0.01395%,C4 0.0121%,C5 0.0172%,C6 0.0166%。
- 30天内发生支架血栓的患者中,76.3%为部分血栓,27.7%为完全血栓;完全血栓患者平均年龄71.4±17岁,部分血栓患者平均年龄71.8±12岁;完全血栓患者中71.43%为女性。
临床怎么用
- 在办公室实验室环境下,可对有症状的非血栓性髂静脉病变患者安全实施髂静脉支架置入术,术后30天血栓风险低。
- 年龄、侧别和CEAP临床分级不应作为限制髂静脉支架置入的因素,因与30天血栓无显著关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The study aims to evaluate the incidence of 30-day thrombosis after iliac vein stent placement, stratified by age, and to analyze long-term follow-up outcomes. METHODS: A retrospective analysis was conducted of 4312 procedures performed in 2642 patients with symptomatic chronic venous insufficiency (Clinical, Etiologic, Anatomic, and Pathophysiologic [CEAP] clinical classes C3-C6) from 2012 to 2024. Patients underwent iliac vein assessment using intravascular ultrasound (IVUS) examination and received stent placement. Follow-up included iliac vein duplex ultrasound assessments at 3 to 7 days postoperatively, with additional evaluations at 3 to 6 months during the first year. For subsequent years, follow-up occurred at 6- to 12-month intervals. Intraoperative heparin was not administered, and postoperative management included daily clopidogrel (Plavix). Stents were assessed for partial and complete thrombosis. RESULTS: The mean age of the study population was 73 years (range, 30-108 years), with 39.30% male and 60.70% female patients. Age distribution by decade, based on the number of nonthrombotic iliac vein lesions treated, was as follows: patients in their 30s (43), 40s (151), 50s (498), 60s (926), 70s (1116), 80s (1035), and >90s (543). Thirty-day thrombosis rates by age group were as follows: 30s (0%), 40s (0.01324%), 50s (0.0200%), 60s (0.0118%), 70s (0.0179%), 80s (0.0116%), and >90s (0.0074%). Thirty-day thrombosis rates by CEAP clinical class were as follows: C3 (0.01395%), C4 (0.0121%), C5 (0.0172%), and C6 (0.0166%). Among patients with thrombosis within 30 days of stent placement, 76.3% experienced partial stent thrombosis and 27.7% experienced complete stent thrombosis. The mean age of patients with complete thrombosis was 71.4 ± 17 years, compared with 71.8 ± 12 years for those with partial thrombosis. Of patients with complete thrombosis, 71.43% were female. Of the 14 patients with complete thrombosis within 30 days, 10 cases occurred between 2012 and 2021, three in 2022, and one in 2023. Binary logistic regression revealed no significant association between 30-day thrombosis and age (P = .719), CEAP clinical class (P = .938), or laterality (P = .326). CONCLUSIONS: Iliac vein stenting for symptomatic nonthrombotic iliac vein lesions is a safe and effective procedure with a low incidence of early thrombosis. Age, laterality, and CEAP clinical class were not significantly associated with 30-day thrombosis outcomes. This study supports the use of iliac vein stenting in patients across a broad spectrum of chronic venous insufficiency severity, demonstrating its effectiveness in an office-based laboratory setting.
引用
- Srivastava S, Ascher E, Hingorani A, et al. Safety of iliac vein stenting in the office-based laboratory: Experience with 4312 nonthrombotic iliac vein lesions. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42542208. doi:10.1016/j.jvsv.2026.102594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。